Serum CCL2 Is a Prognostic Biomarker for Non-Metastatic Castration-Sensitive Prostate Cancer.
Hiroaki IwamotoKouji IzumiRyunosuke NakagawaRen ToriumiShuhei AoyamaTaiki KamijimaTakafumi ShimadaHiroshi KanoTomoyuki MakinoRenato NaitoSuguru KadomotoHiroshi YaegashiShohei KawaguchiTakahiro NoharaKazuyoshi ShigeharaYoshifumi KadonoAtsushi MizokamiPublished in: Biomedicines (2022)
This study is the first to demonstrate serum CCL2 utility as a biomarker to predict OS and CFS in nmCSPC.